If the OTC and micro cap stock sector is a leading indicator of where equity prices are going, the entire stock market could tank 60%. With such macro OTC moves, it’s hard to judge such a promising company as Relief Therapeutics harshly. In fact, for such a small (Swiss) pharma company, its pipeline is becoming well diversified.
Interestingly they keep having good news. The U.S. Patent and Trademark Office has issued a Notice of Allowance for Acer’s patent application No. 17/196,416 for certain claims related to ACER-001.
- The allowed patent claims include pharmaceutical composition claims covering ACER-001’s taste-masked, multi-particulate dosage formulation for oral administration.
- Acer’s patent is expected to be issued in the fourth quarter of 2021 and expire in 2036. In parallel to the patent application efforts in the U.S., they are pursuing similar claims in the European Patent Office to cover ACER-001 as they continue to execute on their plan to submit a Marketing Authorization Application for ACER-001 for the treatment of patients with urea cycle disorders in Europe in Q2/Q3 2022.
The USPTO issues a patent Notice of Allowance after it determines a patent should be granted upon completion of any outstanding administrative requirements.
Acer’s patent is expected to be issued in the fourth quarter of 2021 and expire in 2036. If it receives marketing approval for ACER-001, Acer intends to submit the patent for listing by the U.S. Food and Drug Administration (FDA) in its Approved Drug Products with Therapeutic Equivalence Evaluations or Orange Book.
Growing Company in Weird OTC Reality
With a number of acquisitions and key product pipeline in the works, the OTC price for the stock is now $RLFTF = $0.12. In my view this is one of the most solid micro cap pharma companies with a much higher intrinsic value with signs as early as 2022.
When companies wait for more approval a buy-the-dip strategy is a distinct possibility for savvy investors. I’ve been following the news of this company for quite a while. They had an increase of $0.04 to $0.60 in late July, 2020.
However the bear market for micro cap stocks since February 2021 has been very extreme and you simply cannot deduce much by it except that penny stock retail investors are favoring crypto in the second Bitcoin bull market.
ACER-001 is an investigational product candidate which has not been approved by FDA, the European Medicines Agency (EMA), or any other regulatory authority. There can be no assurance that this product candidate will receive regulatory authority approval for marketing in any territory or become commercially available for the indications under investigation.
You can read the entire press release here. Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate RLF-100™ (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. Once this gets out of the OTC market, you can imagine what it might trade at.
For my top stock picks I write a Newsletter behind a paywall here.
- You can follow Relief on LinkedIn here.